Last reviewed · How we verify
NCT00984516
A Single-site, Placebo-controlled, Double-blind Trial to Investigate the Safety, Tolerability, Systemic Exposure and the Scar-improvement Efficacy of Intradermal Applications of Three Doses of Juvidex (5.64mg/100μl, 2.82mg/100μl and 11.28mg/100μl) Given Once Only or Three Times Within and Between Male and Female Subjects Aged 18-45.
Phase 2 trial testing Juvidex in Cicatrix in 102 participants. Completed in 1 January 2006.
1 January 2006
Quick facts
| Lead sponsor | Renovo |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 102 |
| Start date | 1 August 2004 |
| Primary completion | 1 January 2006 |
| Estimated completion | 1 January 2006 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Juvidex — full drug profile →
- Juvidex — full drug profile →
- Juvidex — full drug profile →
- Juvidex — full drug profile →
- Juvidex — full drug profile →
- Juvidex — full drug profile →
- Placebo
- Placebo
Conditions studied
- Cicatrix — all drugs for Cicatrix →
- Wound-healing — all drugs for Wound-healing →
Sponsor
Renovo — full company profile →
Who can join
Adults 18 to 45, any sex, with Cicatrix or Wound-healing. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
To investigate the scar-improvement efficacy of three doses of intradermal Juvidex given once only and three times in male and female subjects.
Time frame: 12 months
Sponsor's own description
The purpose of this study was to investigate the scar-improvement efficacy of three doses of intradermal Juvidex given once only or three times in male and female subjects and to collect further safety and tolerability data for intradermal Juvidex in male and female subjects.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
New molecular medicine-based scar management strategies.
Arno AI, Gauglitz GG, Barret JP, Jeschke MG. · · 2014 · cited 32× · PMID 24438742 · DOI 10.1016/j.burns.2013.11.010 -
Novel pharmacotherapy for burn wounds: what are the advancements.
Hamblin MR. · · 2019 · cited 17× · PMID 30517046 · DOI 10.1080/14656566.2018.1551880
Verify or expand the search:
- PubMed search for NCT00984516
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cicatrix
Currently open trials in the same condition.
- NCT06122090 — Treatment of Hypopigmented Scars With Bimatoprost · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00984516 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Renovo
- Last refreshed: 24 September 2009
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00984516.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing